---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-037388"
form_type: "8-K"
ticker: "MCRB"
cik: "0001609809"
company_name: "Seres Therapeutics, Inc."
filed_at: "2024-08-15T23:59:59+00:00"
generated_at: "2026-05-31T09:01:17.527480+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Seres files prior financials for proxy on VOWST asset sale; auditor flags going concern

## Summary
- Furnishes 2022-2023 audited financial statements for incorporation in proxy statement related to sale of VOWST microbiome assets.
- Auditor notes substantial doubt about ability to continue as going concern due to recurring losses and negative cash flows.
- Financial statements consistent with prior Form 10-K filed March 5, 2024; no updates for subsequent events.

## SEC filing metadata
- accession: 0001140361-24-037388
- form_type: 8-K
- ticker: MCRB
- cik: 0001609809
- company_name: Seres Therapeutics, Inc.
- filed_at: 2024-08-15T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1609809/000114036124037388/0001140361-24-037388-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1609809/000114036124037388/ny20030749x9_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-037388
- JSON: https://secwatch.observer/filing/0001140361-24-037388.json
- Plain text: https://secwatch.observer/filing/0001140361-24-037388.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.